To, **Date: 16th November, 2026**

The Manager **BSE Limited** **P.J. Towers, Dalal Street** **Mumbai-400001** **(BSE Scrip Code: 544742)**	**The Manager,** **NSE Limited,** **Exchange Plaza, Bandra Kurla Complex,** **Bandra (E), Mumbai- 400051** **(NSE Symbol: SAIPARENT)**

Unit: Sai Parenteral's Limited
Sub: Outcome of Board Meeting held on Monday, 16th November, 2026

***

With reference to the subject cited above, we wish to inform the Exchanges that the Board of Directors of Sai Parenterals Limited (the "Company"), at its meeting held on Monday, November 16, 2026, at 05.30 P.M. at the Registered Office of the Company, considered and approved the following:

1. Board approved for Singing an agreement, through its wholly owned subsidiary SP Analytics Private Limited, to acquire a majority stake in Bion Therapeutics India Private Limited (Bion), a Hyderabad-based branded formulations prescription business company. Bion will become a step-down subsidiary of SAI Parenterals on completion of the deal, which is expected before the end of this month. The transaction will be an all-cash deal. **(Details are attached as Annexure A)**

2. Board Approved for providing the necessary funding support to SP Analytics Private Limited, (Its wholly owned subsidiary company) for completion of the proposed acquisition, through utilisation of the proceeds earmarked for General Corporate Purposes (GCP) from the Company's IPO proceeds and debt, subject to applicable laws and requisite approvals.

The Meeting concluded at 8:10 pm.

Thanking you.
Yours sincerely,
For Sai Parenterals Limited

ASHWANI SINGH BISHT
Digitally signed by ASHWANI SINGH BISHT
Date: 2026.11.16 20:50:44 +05'30'

Ashwani Singh Bisht
Company Secretary & Compliance Officer

Encl. as under

Annexure – A

Details which a listed entity needs to disclose for the events that are deemed to be material as specified in Para A of Part A of Schedule III of the LODR Regulations.

Name of the Target Entity	**M/s. Bion Therapeutics (India) Private Limited**
Details in brief such as size, turnover etc	Turnover of Rupees 28.22 Cr for the half-year ended 30th September, 2026
Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The proposed acquisition of Bion Therapeutics (India) Private Limited is being undertaken by the Company through its wholly owned subsidiary, SP Analytics Private Limited. The transaction shall be evaluated in accordance with the applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with respect to related party transaction requirements. The interest, if any, of the Promoter(s)/Promoter Group in the target entity or the selling shareholders shall be disclosed, as applicable. The proposed acquisition is intended to be undertaken on an arm's-length basis, subject to appropriate assessment and valuation, wherever applicable.
Industry to which the entity being acquired belongs	Pharma Sector
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To provide funding to SP Analytics Private Limited wholly owned subsidiary of the company, with a view to extending financial support to the subsidiary for completing the proposed acquisition of a majority stake in Bion Therapeutics (India) Private Limited. Bion will become a step-down subsidiary of SAI Parenterals on completion of the deal.
Brief Details of any governmental or regulatory approvals required for the acquisition	Not required
Indicative Time period for completion of the acquisition	On or before 30th November, 2026

<table>
<tr><td></td><td colspan="3"></td></tr>
<tr><td>Consideration - whether cash consideration or share swap or any other form and details of the same</td><td colspan="3">Cash</td></tr>
<tr><td>Cost of acquisition and/or the price at which the shares are acquired</td><td colspan="3">Based on the valuation of M/s. Bion Therapeutics (India) Private Limited, as determined by the independent valuer.</td></tr>
<tr><td>Percentage of shareholding / control acquired and / or number of shares acquired</td><td colspan="3">Acquisition of a majority stake and/or controlling interest in Bion Therapeutics (India) Private Limited.</td></tr>
<tr><td>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);</td><td>M/s. Bion Therapeutics (India) Private Limited. was incorporated on 5th September, 2005.</td><td colspan="2">The company was incorporated to undertake testing, analysis and examination of pharmaceuticals, medicines, drugs and other materials.

<table><tr><th>Financial Year</th><th>Total Income in Crore</th></tr><tr><td>2024-25</td><td>47.14</td></tr><tr><td>2025-26</td><td>47.29</td></tr><tr><td>2026-27(For the half-year ended 30th September, 2026</td><td>28.75</td></tr></table></td></tr>
</table>